A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Safety and Efficacy Study of IMCgp100 in Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor: Immunocore
Enrolling: Male and Female Patients
IRB Number: AAAR2515
U.S. Govt. ID: NCT03070392
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study is being done to see if the study drug, IMCgp100, works and is safe as treatment for subjects with uveal melanoma who also test positive for HLA-A*0201. In this study IMCgp100 will be compared to three standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug), or pembrolizumab (an immunotherapy drug). This study is designed to find out if IMCgp100 can make subjects with uveal melanoma live longer and if IMCgp100 can make uveal melanoma tumors stop growing (or shrink).
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with metastatic uveal melanoma? Yes No
Have you previously received chemotherapy, immunotherapy, or target therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162